Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS RECAP

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
1
+0
2
Translate
Report
3535 Views
Comment
Sign in to post a comment